MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
16.78
+0.98 (6.20%)
Nov 20, 2024, 4:00 PM EST - Market closed
MediWound Employees
MediWound had 100 employees as of December 31, 2023. The number of employees increased by 17 or 20.48% compared to the previous year.
Employees
100
Change (1Y)
17
Growth (1Y)
20.48%
Revenue / Employee
$201,410
Profits / Employee
-$199,730
Market Cap
181.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| The Joint | 794 |
| Adaptimmune Therapeutics | 449 |
| 2seventy bio | 274 |
| Stereotaxis | 122 |
| Alpha Tau Medical | 121 |
| Fulcrum Therapeutics | 76 |
| Lineage Cell Therapeutics | 75 |
| Galectin Therapeutics | 14 |
MDWD News
- 22 days ago - MediWound Is A Healthy Investment - Seeking Alpha
- 6 weeks ago - MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers - GlobeNewsWire
- 3 months ago - MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - GlobeNewsWire
- 3 months ago - MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 3 months ago - MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) - GlobeNewsWire
- 3 months ago - MediWound to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers - GlobeNewsWire